New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society

A joint initiative between the National Institute for Health and Clinical Excellence (NICE) and the British Hypertension Society (BHS) has led to the publication of new guidelines for the management of hypertension in the community. Recent trial evidence highlighting the increased incidence of new-o...

Full description

Bibliographic Details
Main Author: Peter Sever
Format: Article
Language:English
Published: SAGE Publications 2006-06-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.3317/jraas.2006.011
_version_ 1797281866265395200
author Peter Sever
author_facet Peter Sever
author_sort Peter Sever
collection DOAJ
description A joint initiative between the National Institute for Health and Clinical Excellence (NICE) and the British Hypertension Society (BHS) has led to the publication of new guidelines for the management of hypertension in the community. Recent trial evidence highlighting the increased incidence of new-onset diabetes in those exposed to beta-blocker-based treatment regimens, with or without diuretics, compared with those based on calcium channel blockers (CCBs) or angiotensin-converting enzyme (ACE-Is) inhibitors has led to a recommendation that in the uncomplicated patient, beta-blockers are no longer considered suitable options for first-line therapy. Together with mounting A evidence that age and ethnicity dictate blood pressure (BP) responsiveness to different classes of antihypertensive drugs, the ACD algorithm is now proposed (formerly ABCD), with ACE inhibitors (ACE-Is) (or angiotensin receptor blockers [ARBs] when ACE-Is are poorly tolerated) preferred in younger patients and or patients and CCBs or diuretics preferred for older patientsand in black patients of any age. Pathophysiological considerations have influenced proposals for combination therapies with CCBs or diuretics added to older patients. Health economic analyses have ACE-Is in younger patients and vice versa in clearly indicated the cost effectiveness of CCBs which are now elevated to equal standing with diuretics in older patients.
first_indexed 2024-03-07T17:03:37Z
format Article
id doaj.art-2e4fb4f406b449de853c89abb4cf195f
institution Directory Open Access Journal
issn 1470-3203
language English
last_indexed 2024-03-07T17:03:37Z
publishDate 2006-06-01
publisher SAGE Publications
record_format Article
series Journal of the Renin-Angiotensin-Aldosterone System
spelling doaj.art-2e4fb4f406b449de853c89abb4cf195f2024-03-03T02:50:46ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32032006-06-01710.3317/jraas.2006.011New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension SocietyPeter SeverA joint initiative between the National Institute for Health and Clinical Excellence (NICE) and the British Hypertension Society (BHS) has led to the publication of new guidelines for the management of hypertension in the community. Recent trial evidence highlighting the increased incidence of new-onset diabetes in those exposed to beta-blocker-based treatment regimens, with or without diuretics, compared with those based on calcium channel blockers (CCBs) or angiotensin-converting enzyme (ACE-Is) inhibitors has led to a recommendation that in the uncomplicated patient, beta-blockers are no longer considered suitable options for first-line therapy. Together with mounting A evidence that age and ethnicity dictate blood pressure (BP) responsiveness to different classes of antihypertensive drugs, the ACD algorithm is now proposed (formerly ABCD), with ACE inhibitors (ACE-Is) (or angiotensin receptor blockers [ARBs] when ACE-Is are poorly tolerated) preferred in younger patients and or patients and CCBs or diuretics preferred for older patientsand in black patients of any age. Pathophysiological considerations have influenced proposals for combination therapies with CCBs or diuretics added to older patients. Health economic analyses have ACE-Is in younger patients and vice versa in clearly indicated the cost effectiveness of CCBs which are now elevated to equal standing with diuretics in older patients.https://doi.org/10.3317/jraas.2006.011
spellingShingle Peter Sever
New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
Journal of the Renin-Angiotensin-Aldosterone System
title New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
title_full New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
title_fullStr New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
title_full_unstemmed New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
title_short New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
title_sort new hypertension guidelines from the national institute for health and clinical excellence and the british hypertension society
url https://doi.org/10.3317/jraas.2006.011
work_keys_str_mv AT petersever newhypertensionguidelinesfromthenationalinstituteforhealthandclinicalexcellenceandthebritishhypertensionsociety